$ORIC

Oric Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer therapies designed to address treatment resistance. Its research and development focuses on hormone-dependent cancers, precision oncology and key tumor dependencies. Its two lead clinical-stage product candidates are rinzimetostat, an inhibitor of PRC2 being studied for advanced prostate cancer, and enozertinib, an inhibitor targeting EGFR exon 20 and atypical mutations being studied in non-small cell lung cancer. ORIC evaluates its candidates in clinical trials and aims to develop and commercialize therapies, alone or with partners. It owns or licenses worldwide development and commercialization rights to its programs, with enozertinib rights excluding the People's Republic of China, Hong Kong, Macau and Taiwan. The company also has clinical trial collaborations with Johnson & Johnson and Bayer. ORIC is headquartered in South San Francisco, California.

AlphAI earnings readQ3 FY2026 · NOV 16ORIC reports Q3 2026 net loss of $(48,076) thousand as R&D expenses rise to $43.4 millionVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

4
0
0
—
$189K
Piscitelli Dominic
100%
See all $ORIC insider activity →
Med

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

Oric Pharmaceuticals stock maintained at Buy by BTIG, $26 target

BTIG maintained a Buy rating and $26.00 price target on Oric Pharmaceuticals (ORIC) after its Q3 earnings. The stock trades at $7.52, near its 52-week low. The company reported positive data for rinzimetostat and enozertinib, with key trials expected in 2027. ORIC has $345M in cash, sufficient for operations into 2028. Stifel also raised its price target to $18.

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo

ORIC sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning ORIC (Oric Pharmaceuticals, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.

Recent ORIC coverage spans financial news, earnings and market movers.

In the last 30 days, ORIC insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($189K). The most active reporter was Piscitelli Dominic, Chief Financial Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving ORIC

AlphAI scores every news story that mentions ORIC with an AI model for sentiment and relevance, and aggregates insider trades from Oric Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ORIC

Score

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

Oric Pharmaceuticals stock maintained at Buy by BTIG, $26 target

BTIG maintained a Buy rating and $26.00 price target on Oric Pharmaceuticals (ORIC) after its Q3 earnings. The stock trades at $7.52, near its 52-week low. The company reported positive data for rinzimetostat and enozertinib, with key trials expected in 2027. ORIC has $345M in cash, sufficient for operations into 2028. Stifel also raised its price target to $18.

$ORICMedAI 8/10Earnings

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo

$ORICMedAI 8/10

A prostate cancer drug may make hormone-blocking treatment work better

ORIC Pharmaceuticals presented preclinical and translational data at ESMO Congress 2026, showing that rinzimetostat, its prostate cancer drug, enhances sensitivity to androgen receptor inhibition. The data suggest potential advantages over EZH2 inhibitors, including maintained effectiveness against resistance mutations and a favorable safety profile. ORIC's chief scientific officer highlighted the drug's potential best-in-class profile and its ongoing evaluation in the Himalayas-1 Phase 3 trial.

Related tickers